Manufacturers report positive topline results from phase 3 clinical trial evaluating Setmelanotide in Bardet-Biedl and Alström syndromes

In the study, 34.5% of patients with these ultra-rare genetic diseases (a significant symptom being hyperphagia) given this melanocortin-4 receptor agonist achieved a 10% reduction in bodyweight vs baseline.

Source:

Biospace Inc.